Nektar CEO awarded 57,200 stock options

Howard W. Robin, President & CEO of Nektar Therapeutics, reported an acquisition of 57,200 stock options linked to common stock.

Rhea-AI Filing Summary

Howard W. Robin, President & CEO of Nektar Therapeutics, reported an acquisition of 57,200 stock options linked to common stock. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan, have a $15.15 exercise price, and expire on December 12, 2032. The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied and stated that the options vested on July 24, 2026, while time-based vesting continues on a monthly pro-rata basis over five years from the grant date.

Insider Trade Summary

Grant/Award: 57,200 shares

Grant/Award 1 txn

Insider ROBIN HOWARD W

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1, F2	57,200	$0.00	$0.00

Holdings After Transaction: Stock Option — 57,200 contracts (Direct)

Footnotes (2)

1. F1. These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.
2. F2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).

Key Figures

Stock options acquired: 57,200 options Exercise price: $15.15 per share Expiration date: December 12, 2032 +4 more

7 metrics

Stock options acquired 57,200 options Grant, award, or other acquisition of derivative securities linked to common stock

Exercise price $15.15 per share Conversion or exercise price of the stock options

Expiration date December 12, 2032 Expiry of the reported stock options

Grant date December 13, 2024 Date the options were granted under the 2017 Amended and Restated Performance Incentive Plan

Performance vesting satisfaction date July 23, 2026 Committee determined performance-based vesting requirement was satisfied

Vesting date referenced July 24, 2026 Stock options stated to have vested, subject to remaining time-based vesting requirements

Time-based vesting period 5 years Monthly pro-rata vesting over five years from the grant date

Key Terms

performance-based vesting requirement, time-based vesting, 2017 Amended and Restated Performance Incentive Plan, Organization and Compensation Committee

4 terms

performance-based vesting requirement financial

"the performance-based vesting requirement for these stock options was satisfied"

time-based vesting financial

"The time-based vesting is on a monthly pro-rata basis over a period"

Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.

2017 Amended and Restated Performance Incentive Plan financial

"These stock options were granted on December 13, 2024 under the 2017 Amended"

Organization and Compensation Committee financial

"The Organization and Compensation Committee of the Board of Directors"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nektar Therapeutics (NKTR) report for Howard W. Robin?

Nektar Therapeutics reported that President & CEO Howard W. Robin acquired 57,200 stock options linked to common stock, recorded as a grant or award acquisition on July 24, 2026, under the company’s 2017 Amended and Restated Performance Incentive Plan.

How many stock options did the Nektar (NKTR) CEO receive and at what exercise price?

Howard W. Robin holds 57,200 stock options with an exercise price of $15.15 per share. These derivative securities relate to an equal number of shares of Nektar Therapeutics common stock and are reported as directly owned following the transaction.

What are the vesting terms of the CEO’s stock options reported by NKTR?

The options were granted with both performance-based and time-based vesting. Time-based vesting occurs on a monthly pro-rata basis over five years from the December 13, 2024 grant date, and performance-based conditions were later determined to be satisfied.

When were the performance-based conditions for Nektar (NKTR) CEO options satisfied and vested?

The Organization and Compensation Committee determined on July 23, 2026 that the performance-based requirement was satisfied, and stated that the 57,200 stock options vested on July 24, 2026, subject to remaining time-based vesting requirements continuing over the five-year schedule.

When do the Nektar Therapeutics (NKTR) CEO stock options expire?

The 57,200 stock options held by Howard W. Robin expire on December 12, 2032. They were granted on December 13, 2024 and carry a $15.15 exercise price, providing a defined window for potential future exercise of these derivative securities.

Were Howard W. Robin’s Nektar (NKTR) option transactions under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as being pursuant to such a plan, indicating these reported option-related events are not affirmed as made under a pre-arranged Rule 10b5-1 trading arrangement in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 06:35 PM Accepted by SEC EDGAR 07/24/2026 - 06:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBIN HOWARD W

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(1)	$15.15	07/24/2026		A		57,200		(2)	12/12/2032	Common Stock	57,200	$0.00	57,200	D

Explanation of Responses:

1. These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.

2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).

	Elizabeth Zhang, Attorney-in-Fact	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)